119 related articles for article (PubMed ID: 27185377)
1. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
2. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
[TBL] [Abstract][Full Text] [Related]
3. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
Kaderi MA; Kanduri M; Buhl AM; Sevov M; Cahill N; Gunnarsson R; Jansson M; Smedby KE; Hjalgrim H; Jurlander J; Juliusson G; Mansouri L; Rosenquist R
Haematologica; 2011 Aug; 96(8):1153-60. PubMed ID: 21508119
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.
Falchi L; Keating MJ; Wang X; Coombs CC; Lanasa MC; Strom S; Wierda WG; Ferrajoli A
Cancer; 2013 Sep; 119(17):3177-85. PubMed ID: 24022787
[TBL] [Abstract][Full Text] [Related]
5. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
[TBL] [Abstract][Full Text] [Related]
6. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
Gonzalez D; Else M; Wren D; Usai M; Buhl AM; Parker A; Oscier D; Morgan G; Catovsky D
Haematologica; 2013 Feb; 98(2):274-8. PubMed ID: 22899580
[TBL] [Abstract][Full Text] [Related]
7. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Chauzeix J; Laforêt MP; Deveza M; Crowther L; Marcellaud E; Derouault P; Lia AS; Boyer F; Bargues N; Olombel G; Jaccard A; Feuillard J; Gachard N; Rizzo D
Cancer Med; 2018 Jun; 7(6):2621-2628. PubMed ID: 29745034
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Heerema NA; Muthusamy N; Zhao Q; Ruppert AS; Breidenbach H; Andritsos LA; Grever MR; Maddocks KJ; Woyach J; Awan F; Long M; Gordon A; Coombes C; Byrd JC
Haematologica; 2021 Jun; 106(6):1608-1615. PubMed ID: 32414849
[TBL] [Abstract][Full Text] [Related]
9. NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases.
Zou Y; Fan L; Xia Y; Miao Y; Wu W; Cao L; Wu J; Zhu H; Qiao C; Wang L; Xu W; Li J
Cancer Med; 2018 May; 7(5):1689-1696. PubMed ID: 29573199
[TBL] [Abstract][Full Text] [Related]
10. Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia.
Zhang J; Xiang Y; Ding L; Keen-Circle K; Borlawsky TB; Ozer HG; Jin R; Payne P; Huang K
BMC Bioinformatics; 2010 Oct; 11 Suppl 9(Suppl 9):S5. PubMed ID: 21044363
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.
Rossi FM; Del Principe MI; Rossi D; Irno Consalvo M; Luciano F; Zucchetto A; Bulian P; Bomben R; Dal Bo M; Fangazio M; Benedetti D; Degan M; Gaidano G; Del Poeta G; Gattei V
J Transl Med; 2010 Mar; 8():23. PubMed ID: 20211015
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.
Marasca R; Maffei R; Morselli M; Zucchini P; Castelli I; Martinelli S; Fontana M; Ravanetti S; Curotti M; Leonardi G; Cagossi K; Partesotti G; Torelli G
J Mol Diagn; 2005 Nov; 7(5):566-74. PubMed ID: 16258154
[TBL] [Abstract][Full Text] [Related]
13. [Biological characteristics and clinical significance of stereotyped B-cell receptor in chronic lymphocytic leukemia].
Qiu TL; Li JY; Xia Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):197-202. PubMed ID: 38604800
[TBL] [Abstract][Full Text] [Related]
14. Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia.
Huet S; Bouvard A; Ferrant E; Mosnier I; Chabane K; Salles G; Michallet AS; Hayette S; Sujobert P
Leukemia; 2020 Aug; 34(8):2257-2259. PubMed ID: 31996767
[No Abstract] [Full Text] [Related]
15. Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course.
Angotzi F; Cellini A; Ruocco V; Cavarretta CA; Zatta I; Serafin A; Pravato S; Pagnin E; Bonaldi L; Frezzato F; Facco M; Piazza F; Trentin L; Visentin A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539430
[TBL] [Abstract][Full Text] [Related]
16. Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70.
Kaplan D; Sun Z; Tallman MS; Flinn IW; Xiao W; Caimi PF; Kaye NM; Lazarus HM
Cytometry A; 2014 Sep; 85(9):798-808. PubMed ID: 24845539
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
Nadeu F; Clot G; Delgado J; Martín-García D; Baumann T; Salaverria I; Beà S; Pinyol M; Jares P; Navarro A; Suárez-Cisneros H; Aymerich M; Rozman M; Villamor N; Colomer D; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer ÁR; Puente XS; López-Otín C; López-Guillermo A; Enjuanes A; Campo E
Leukemia; 2018 Mar; 32(3):645-653. PubMed ID: 28924241
[TBL] [Abstract][Full Text] [Related]
18. Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.
Degheidy HA; Venzon DJ; Farooqui MZ; Abbasi F; Arthur DC; Wilson WH; Wiestner A; Stetler-Stevenson MA; Marti GE
Cytometry B Clin Cytom; 2011 Sep; 80(5):309-17. PubMed ID: 21472850
[TBL] [Abstract][Full Text] [Related]
19. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Kipps TJ; Rassenti L; Krupnik D; Lerner S; LaPushin R; Xiao L; Huang X; Werner L; Neuberg D; Kantarjian H; O'Brien S; Wierda WG; Keating MJ; Rosenwald A; Burger JA
Blood; 2011 Feb; 117(5):1662-9. PubMed ID: 21115978
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis.
Papageorgiou SG; Kontos CK; Diamantopoulos MA; Bouchla A; Glezou E; Bazani E; Pappa V; Scorilas A
Dis Markers; 2017; 2017():2046545. PubMed ID: 29463948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
